Cipla Limited, along with its multiple subsidiaries, is responsible for the manufacture and sale of pharmaceutical goods in India. It provides a variety of formulations and active pharmaceutical ingredients in various aspects like urology, ophthalmology, malaria, oncology, neurosciences, women’s and children’s health, hepatitis, critical care, osteoporosis, and infectious diseases.
The company provides multiple inhalation therapy devices like nasal sprays, metered-dose inhalers, accessory devices, dry powder inhalers, and nebulizers. Apart from manufacturing and selling these products in India, it also exports to Russia, the Middle East, Asia, Australia, New Zealand, and Latin America and other regions internationally.
On 17th of August in 1935, Cipla got registered as a public limited with a capital of Rs. 6 lakh and is a Mumbai based Company in India. During the Second World War, when the drug supplies were topped in 1941, the company started to produce fine chemicals. At this point, Cipla dedicated its facilities to provide a variety of ingenious drugs.
About Company Information:
Within the next two decades after the inception of the Second World War, in 1960, the company started its operations in Vikhroli, Mumbai. This was their second plant. At this unit, they produced fine chemicals related to natural products. Ampicillin was manufactured for the first time in the country in 1968 by Cipla. To cultivate medicinal plants, the company then started their Agricultural Research Division, located in Bangalore, in the year 1972.
In 1982, the company started operating in its fourth manufacturing unit located in Patalganga, Maharashtra. The company collaborated with the National Chemical Laboratory in Pune, in the year 1984 to produce anti-cancer drugs like vincristine and vinblastine. Collaborating with Indian Institute of Chemical Technology, in 1991, a drug considered to be a breakthrough in chemotherapy, named etoposide was launched by the company. Later on, an antiretroviral drug called zidovudine was also manufactured by the company in association with Indian Institute of Chemical Technology.
Nevirapine, an antiretroviral drug used to stop AIDS transmission in a child from a mother, was launched by the company in 1999. Cipla was the first company, outside of Europe and U.S.A, which began CFC-free-inhalers, in the year 2000. In February in 2007, the company allied with the Drugs for Neglected Diseases Initiative for developing a new anti-malarial drug. This was a worldwide initiative taken by the company with a non-profit organization like DNDI.
In April of 2010, the company started its operations for commercial production of a variety of pharmaceutical formulations at their SEZ project in Indore, MP. On the 21st of July, 2012, Cipla revealed that they were to collaborate with DNDi (a non-profit R&D organization) for developing an improved form of antiretroviral (ARV) combo therapy which will specifically treat kids affected by HIV/AIDS.
On the 17th of April, 2013, Cipla announced that they would be the first to launch a biosimilar of Etanercept in the country which will be targeted to treat rheumatic disorders. On the 20th of February in 2014, Cipla announced their alliance with MSD which would give them a non-exclusive license using which they would sell raltegravir 400mg tablet (a drug from MSD) along with marketing and distribution of the drug but down under a different brand name.
In February 2015, Cipla revealed to have been awarded a Global Fund ARV Tender which is worth USD 188.95 million for developing antiretroviral drugs.
On the 12th of October, 2016, Cipla announced the formal closing of US FDA inspection that was conducted in July-August in the year 2015. Cipla was given the establishment inspection report by the FDA, and it was held AT THE Indore Unit of the company. On the 30th of November, 2017, Cipla publicized the fact that the company had received approval from the World Health Organization (WHO) for a product name Q-TIB, which is essentially a combination of novel fixed-dose within a single tablet form. This was the first combination to ever exist in the world.
How Cipla Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
Cipla Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
Cipla Ltd, Competitors and Sector Peers:
Alembic Pharmaceuticals Ltd. ALEPHA
Alkem Laboratories Ltd. ALKLAB
Alpa Laboratories Ltd. ALPLAB
Ambalal Sarabhai Enterprises Ltd. AMBSAR
AstraZeneca Pharma India Ltd. ASTZEN
Bafna Pharmaceuticals Ltd. BAFPHA
Bajaj Healthcare Ltd. BAJHEA
Concord Drugs Ltd. CONDRU
Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
Divi's Laboratories Ltd. DIVIL
Dr. Reddy's Laboratories Ltd. DR
GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
Glenmark Pharmaceuticals Ltd. GLEPHL
IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
Lincoln Pharmaceuticals Ltd. LINPHA
Madhuveer Com 18 Network Ltd. TOHPHA
Mahavir Advanced Remedies Ltd. INDAME
Makers Laboratories Ltd. MAKLAB
Natural Capsules Ltd. NATCAP
Ranbaxy Laboratories Ltd. RANLAB
Sharon Bio-Medicine Ltd. SHAPHA
Sun Pharmaceutical Industries Ltd. SUN28
Zenith Healthcare Ltd. ZENHEA